TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06487624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB301
Description: HCB301 administered via. intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB301
Description: HCB301 administered via. intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB301
Description: HCB301 administered via. intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB301
Description: HCB301 administered via. intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB301
Description: HCB301 administered via. intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB301
Description: HCB301 administered via. intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCB301
Description: HCB301 administered via. intravenous (IV) infusion.
Study: NCT06641973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic balance rehabilitation with hunova® robotic platform
Description: The G-Hun will perform robotic balance treatment with the hunova® robotic platform lasting 30 minutes per session, 2 times a week for 5 weeks, in addition to the services provided in their clinical pathway.
Study: NCT06250790

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography and FFRct analysis
Description: A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
Study: NCT05551325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronobundle - light
Description: Bright daytime light from 09:00 to 13:00 starting on day 1. The light will be 10,000 lux at 12 and provide a minimal intensity of 1,250 lux at the angle of the eye (30 to 36 distance). The light has a temperature of 5,000 Kelvin indicating a high blue wavelength content which should maximize circadian effects (validated device Sunbox Lighting, Maryland). Following the 09:00 to 13:00 bright light, the room lights will remain on and the curtains will remain open to maximize daytime light exposure while not decreasing bright light tolerance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronobundle - feeding
Description: For patients receiving enteral feeds, time-restricted (daytime) intermittent feeding will include 4 meals delivered at 08:00, 12:00, 16:00 and 20:00. Each meal will include one-fourth of the recommended daily tube feed volume.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronobundle - mobility
Description: While in the MICU, exercise/mobility sessions led by physical therapy or occupational therapy providers will occur twice daily between 09:00 and 16:00 (i.e., one additional session beyond usual care); intensity will be determined by clinical status and documented in the chart by our physical therapy service. Patients in other hospital locations (e.g., general medical ward post-MICU discharge) will receive one additional session beyond usual care via a study staff-led exercise/mobility session; intensity will be determined by clinical status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chronobundle - sleep
Description: Overnight sleep promotion will occur between 22:00 and 06:00 with a more restricted sleep period between 00:00 and 04:00. This will be achieved by rescheduling non-urgent care. There will be no changes to urgent care. Additionally, room lights will be dimmed, curtains drawn, and room doors closed. Television screens will be fitted with blue light-blocking filters.
Study: NCT05032872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Exergame Treatment Group
Description: * Physical activity tracking, walk to grow flowers and plant their own garden~* Follow workout tutorials~* Daily steps tracked by Fitbit and workout log tracked by the app~* Daily reminders to wear Fitbit, use the app, and share stories to unlock new flowers to grow~* Includes social features: like, reply, and see other's stories, and share their stories; Access to other people's gardens~* In-app rewards (unlock new flowers to grow each week) if participants post stories

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: * Physical activity tracking, walk to grow flowers and plant their own garden~* Follow workout tutorials~* Daily steps tracked by Fitbit and workout log tracked by the app~* Daily reminders to wear Fitbit and use the app
Study: NCT05456139

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Families in the Treatment as Usual (TAU) condition will receive usual care and EI services in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Social Interaction Mobile Coaching (ESI-MC)
Description: The ESI-MC coach will offer 24 weekly sessions for the 6-month ESI-MC condition. The parent will be the focus of training. Each session includes: setting the stage to develop that session's agenda; intervention implementation with these coaching steps: a) review the target, b) use guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to support caregiver reflection and independence in the activity, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and summarize plans for deliberate practice between sessions. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided online course and companion to the online group education meetings to engage families in the content of the online course and provide support through interaction with other families. Families will also participate in TAU usual care and EI services in their community.
Study: NCT05019404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional anterior temporal lobectomy (FATL)
Description: Patients are placed in the supine position with the head contralaterally rotated 30°. The 3D model of incision and bone flap is printed prior to surgery by the slicer software based on the MRI data. Slightly curve incision with the length of about 6 cm in the temporal region is marked according to the 3D model. Temporal craniotomy via small bone window with the diameter of about 3 cm is performed. From the temporal pole along T1 about 5 cm posteriorly, temporal horn is opened by dissecting the middle temporal gyrus. The head of temporal horn is exposed. The amygdala is resected. Then, the parahippocampal gyrus and hippocampus are en bloc resected. The lateral temporal lobotomy is easy due to large view following the removal of mesial structures. The lateral posterior temporal lobotomy is no more than 5 cm from the temporal pole.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior temporal lobectomy (ATL)
Description: Patients are placed in the supine position with the head contralaterally rotated 30°. Large frontotemporal craniotomy is performed. Question mark-shaped incision with the length of 20- 25 cm in the frontotemporal region is marked. The size of the bone flap is approximately 5×7 cm for the exposure of lateral temporal lobe. ATL consists of en bloc resection of the anterior 5 cm of lateral temporal lobe, followed by the removal of mesial structures including the amygdala, parahippocampal gyrus, and hippocampus.
Study: NCT05085171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced care package
Description: The intervention is an improved package of care for patients with advanced HIV disease with point of care CD4 testing, more sensitive screening tests for opportunistic infections and more intensive pre-emptive treatment for opportunistic infections
Study: NCT04766359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Compare the effectiveness and safety of paclitaxel (albumin-bound) combined with radiotherapy and cisplatin combined with radiotherapy in the treatment of early nasopharyngeal carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Compare the effectiveness and safety of paclitaxel (albumin-bound) combined with radiotherapy and cisplatin combined with radiotherapy in the treatment of early nasopharyngeal carcinoma.
Study: NCT06371638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: General anaesthesia for subjects in Group D was maintained by target-controlled infusion (TCI) dexmedetomidine (Dyck mode) with target plasma of 1 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: General anaesthesia for subjects in Group D was maintained by target-controlled infusion (TCI) dexmedetomidine (Dyck mode) with target plasma of 1 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: General anaesthesia for subjects in Group I was maintained by inhalation anaesthesia using sevoflurane at 0.8% concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: General anaesthesia for subjects in Group I was maintained by inhalation anaesthesia using sevoflurane at 0.8% concentration.
Study: NCT04650542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-3000
Description: small molecule, multi-ion channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: serotonin uptake inhibitor, CYP2D6 inhibitor
Study: NCT06256328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose, once daily
Study: NCT05416944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized blood pressure management
Description: Personalized blood pressure management: Intraoperative mean arterial pressure will be maintained at least at the mean nighttime mean arterial pressure (assessed using preoperative automated blood pressure monitoring) with a minimum mean arterial pressure of 65 mmHg, and maximum mean arterial pressure of 110 mmHg.
Study: NCT04646967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: See active comparator description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: See active comparator description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: See active comparator description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: See active comparator description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: See experimental arm description
Study: NCT05591261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePREP
Description: 6-session online psychoeducational program with supporting coach calls
Study: NCT04864262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photovoice
Description: Photovoice is a method that uses photographs and dialogue to share experiences, understand an issue and promote positive change. Group meetings will be held four times throughout the photovoice intervention. The goals of the group meetings are to share knowledge about falls and fall prevention, identify commonalities in the issues raised by the participants, and discuss ways in which these issues could be addressed, both at individual and societal levels. For two photo assignments, participants will be asked to take 4-6 pictures for an assigned question. The question for photo assignment #1 will be 'What decreases your likelihood of falling?' The question for photo assignment #2 will be 'How do you reduce the risk of falling so that you can participate in meaningful activities?' Following each photo assignment, participants will complete an individual semi-structured interview with the peer mentor and the research trainee, who will have a background in physical or occupational therapy.
Study: NCT05036681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: tablets by mouth 1 time every day
Study: NCT06310408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal mask
Description: Give interface nasal mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal prong
Description: give interface nasal prong
Study: NCT05036681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein over about 30-60 minutes on Day 1 of all cycles
Study: NCT06098989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radio frequency ablation
Description: Radio frequency ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radio frequency ablation
Description: Radio frequency ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radio frequency ablation
Description: Radio frequency ablation
Study: NCT05981924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative Music Therapy
Description: Music therapist will play customized music in the perioperative period on the basis of oxycodone analgesia
Study: NCT05415306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Attention bias modification (ABM) is a procedure for treatment of depression, with the intention of supplementing cognitive behavioural therapy (CBT) or as a treatment on its own. ABM procedures modify attention biases in emotional disorders, resulting in subjects learning to deploy their attention toward the more positive stimuli (Jonassen et al., 2018). A computerized attention bias modification intervention for depression involves repeatedly redirecting the attention of the subject away from emotionally relevant threat cues, and towards neutral (non-threatening) stimuli (Amir et al., 2009). The location of the probe will replace the relatively positive stimulus in the pair with 100% probability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deep-breathing training
Description: In most deep breathing studies, participants are required to alter their breathing pattern to a specific frequency for a specific duration of time. In the present study, participants will be required to perform deep-breathing at a rate of 6 breaths per minute for 9 minutes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: This condition is identical to the Attention Bias Modification condition with the except of the location of the probe, which replaces the positive, negative, and neutral stimuli with equal probability. This control procedure is not expected to modify any underlying biases present.
Study: NCT05634655

Intervention type: OTHER
Intervention: no interventions between two groups
Description: no interventions between two groups

Intervention type: OTHER
Intervention: no interventions between two groups
Description: no interventions between two groups
Study: NCT05626569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 combined with SBRT
Description: Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
Study: NCT06441370

Intervention type: PROCEDURE
Intervention: waterbirth
Description: waterbirth: laboured for all or part of the first stage of labour and remained in the water for birth of newborn
Study: NCT05401877

Intervention type: PROCEDURE
Intervention: therapies for breast cancer
Description: the type of tumor removal surgery, combined therapy

Intervention type: PROCEDURE
Intervention: therapies for breast cancer
Description: the type of tumor removal surgery, combined therapy
Study: NCT06049992

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation with conduction system pacing using Lumenless leads
Description: Pacemaker implantation for conduction system pacing will be done using leads without internal lumen (Lumenless; Medtronic Selectsecure 3830, Minneapolis, USA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation with conduction system pacing using Stylet-driven leads
Description: Pacemaker implantation for conduction system pacing will be done using leads with internal lumen and retractable helix (Tendril STS 2088TC, Abbott, Inc., USA; Solia S60, Biotronik, SE \& Co., KG, Germany; Ingevity +, Boston Scientific, Marlborough, MA, USA)
Study: NCT05872152

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FTIR results
Description: Weekly transmission of FTIRS typing of ESBL-E to centers
Study: NCT06280040

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical examination and multimodal ocular imaging
Description: Imaging consists of sonography, fundus photography, oximeter, optical coherence tomography angiography, and Microperimetry.
Study: NCT06333353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real RepetitiveTranscranial Magnetic Stimulation 5 sessions
Description: 5 consecutive treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximately 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RepetitiveTranscranial Magnetic Stimulation 5 sessions
Description: 5 consecutive sham treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximately 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real RepetitiveTranscranial Magnetic Stimulation 10 sessions
Description: 10 consective treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximatly 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham RepetitiveTranscranial Magnetic Stimulation 10 sessions
Description: 10 consective sham treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximatly 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention.
Study: NCT05945004

Intervention type: OTHER
Intervention: ChatGPT-4
Description: Subjects' clinical records will be read by ChatGPT-4 to write preoperative visit sheets.

Intervention type: OTHER
Intervention: Clinician
Description: Subjects' clinical records will be read by clinicians to write preoperative visit sheets.
Study: NCT06000033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin+Anlotinib
Description: Disitamab Vedotin:2 mg/kg，ivgtt，d1-14/28day/cycle Anlotinib: 12mg once daily (taken before meals) orally, continuously for 2 weeks followed by a 1-week break. Each cycle consists of 21 days.
Study: NCT05216159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA behavioural counselling + weekly HAPA worksheets
Description: Behavioural counselling grounded in the Health Action Process Approach (HAPA; ie., action planning and coping planning) paired with weekly HAPA based worksheets delivered through a mobile application, SEMA3, to reduce consecutive workplace sedentary behaviour.
Study: NCT05181371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided ESP Block with Programmed Intermittent Bolus (PIB) for VATS
Description: Programmed Intermittent Bolus (PIB) of Levobupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided ESP Block with Continuous Infusion (CI) for VATS
Description: Continuous Infusion (CI) of Levobupivacaine